These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 20514488)

  • 1. Neurotoxic protein oligomerisation associated with polyglutamine diseases.
    Hands SL; Wyttenbach A
    Acta Neuropathol; 2010 Oct; 120(4):419-37. PubMed ID: 20514488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autophagy in polyglutamine disease: Imposing order on disorder or contributing to the chaos?
    Cortes CJ; La Spada AR
    Mol Cell Neurosci; 2015 May; 66(Pt A):53-61. PubMed ID: 25771431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyglutamine expansion mutation yields a pathological epitope linked to nucleation of protein aggregate: determinant of Huntington's disease onset.
    Sugaya K; Matsubara S; Kagamihara Y; Kawata A; Hayashi H
    PLoS One; 2007 Jul; 2(7):e635. PubMed ID: 17653262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The interplay between PolyQ and protein context delays aggregation by forming a reservoir of protofibrils.
    Bulone D; Masino L; Thomas DJ; San Biagio PL; Pastore A
    PLoS One; 2006 Dec; 1(1):e111. PubMed ID: 17205115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased aggregation of polyleucine compared with that of polyglutamine in dentatorubral-pallidoluysian atrophy protein.
    Suzuki Y; Jin C; Yazawa I
    Neurosci Lett; 2013 Sep; 552():156-61. PubMed ID: 23933208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-domain misfolding: understanding the aggregation pathway of polyglutamine proteins.
    Saunders HM; Bottomley SP
    Protein Eng Des Sel; 2009 Aug; 22(8):447-51. PubMed ID: 19589877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arginine is a disease modifier for polyQ disease models that stabilizes polyQ protein conformation.
    Minakawa EN; Popiel HA; Tada M; Takahashi T; Yamane H; Saitoh Y; Takahashi Y; Ozawa D; Takeda A; Takeuchi T; Okamoto Y; Yamamoto K; Suzuki M; Fujita H; Ito C; Yagihara H; Saito Y; Watase K; Adachi H; Katsuno M; Mochizuki H; Shiraki K; Sobue G; Toda T; Wada K; Onodera O; Nagai Y
    Brain; 2020 Jun; 143(6):1811-1825. PubMed ID: 32436573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human cytomegalovirus UL97 kinase prevents the deposition of mutant protein aggregates in cellular models of Huntington's disease and ataxia.
    Tower C; Fu L; Gill R; Prichard M; Lesort M; Sztul E
    Neurobiol Dis; 2011 Jan; 41(1):11-22. PubMed ID: 20732421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyglutamine induced misfolding of huntingtin exon1 is modulated by the flanking sequences.
    Lakhani VV; Ding F; Dokholyan NV
    PLoS Comput Biol; 2010 Apr; 6(4):e1000772. PubMed ID: 20442863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Towards the treatment of polyglutamine diseases: the modulatory role of protein context.
    Robertson AL; Bottomley SP
    Curr Med Chem; 2010; 17(27):3058-68. PubMed ID: 20629626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Putting huntingtin "aggregation" in view with windows into the cellular milieu.
    Hatters DM
    Curr Top Med Chem; 2012; 12(22):2611-22. PubMed ID: 23339311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity.
    Sakahira H; Breuer P; Hayer-Hartl MK; Hartl FU
    Proc Natl Acad Sci U S A; 2002 Dec; 99 Suppl 4(Suppl 4):16412-8. PubMed ID: 12189209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggregation of polyglutamine-expanded ataxin-3 sequesters its specific interacting partners into inclusions: implication in a loss-of-function pathology.
    Yang H; Li JJ; Liu S; Zhao J; Jiang YJ; Song AX; Hu HY
    Sci Rep; 2014 Sep; 4():6410. PubMed ID: 25231079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spontaneous self-assembly of pathogenic huntingtin exon 1 protein into amyloid structures.
    Trepte P; Strempel N; Wanker EE
    Essays Biochem; 2014; 56():167-80. PubMed ID: 25131594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease.
    Matos CA; de Macedo-Ribeiro S; Carvalho AL
    Prog Neurobiol; 2011 Sep; 95(1):26-48. PubMed ID: 21740957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1.
    Meriin AB; Zhang X; He X; Newnam GP; Chernoff YO; Sherman MY
    J Cell Biol; 2002 Jun; 157(6):997-1004. PubMed ID: 12058016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-Terminal Fragments of Huntingtin Longer than Residue 170 form Visible Aggregates Independently to Polyglutamine Expansion.
    Chen MZ; Mok SA; Ormsby AR; Muchowski PJ; Hatters DM
    J Huntingtons Dis; 2017; 6(1):79-91. PubMed ID: 28339398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins.
    Krobitsch S; Lindquist S
    Proc Natl Acad Sci U S A; 2000 Feb; 97(4):1589-94. PubMed ID: 10677504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformational diseases: structural studies of aggregation of polyglutamine proteins.
    Papaleo E; Invernizzi G
    Curr Comput Aided Drug Des; 2011 Mar; 7(1):23-43. PubMed ID: 20807186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ataxin-1 fusion partners alter polyQ lethality and aggregation.
    Rich T; Varadaraj A
    PLoS One; 2007 Oct; 2(10):e1014. PubMed ID: 17925862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.